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ity compared with treatment of more proximal vessels.6
Causes of failure after angioplasty/stent placement in both
iliac and femoral locations include acute thrombosis, recoil
of the treated artery, intimal hyperplasia, and progression
of disease outside of the treated segment. For both iliac
and femoral occlusive lesions, open surgical bypass has
proven at least as effective and durable as, and usually
superior to, angioplasty with or without adjunctive stent-
ing. In an attempt to combine the advantages of lesser
invasiveness of endoluminal therapy with the improved
outcomes associated with graft placement, endoluminal
stent grafting has been explored. After plaque fracture
(balloon angioplasty) or removal (debulking) is performed
to allow adequate expansion of the endoprosthesis, the
vessel is relined with graft material. Debulking (removal of
atherosclerotic plaque volume) may be required in arterial
segments where the radial expansion of the vessel wall is
constrained. This can occur in areas of severe, unyielding
calcific arterial plaque formation or in locations where
external structures limit overall vessel size such as the
adductor hiatus. Several homemade and manufactured
endografts are currently being evaluated. The Hemobahn
endoprosthesis (WL Gore and Associates, Inc, Flagstaff,
Ariz) is designed for management of occlusive lesions in
the iliac and femoral system and is the focus of this report.
THE HEMOBAHN ENDOPROSTHESIS
The Hemobahn endoprosthesis is a self-expanding
endoluminal prosthesis. The prosthesis is composed of an
ultrathin (100-µm wall thickness, 30-µm internodal dis-
tance) expanded polytetraflouroethylene graft on the
luminal surface attached to self-expanding nitinol (nickel-
titanium) stent (Fig 1). The device is premounted on a
delivery catheter with a unique deployment system.
Deployment occurs by pulling a deployment knob located
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The Hemobahn endoprosthesis: A self-expanding
polytetrafluoroethylene-covered endoprosthesis
for the treatment of peripheral arterial occlusive
disease after balloon angioplasty
Brian G. Rubin, MD, and Gregorio A. Sicard, MD, St. Louis, Mo
Endoluminal management of occlusive arterial disease has previously been limited to balloon angioplasty, either alone or
with stent placement. This article discusses the Hemobahn endoprosthesis, a polytetraflouroethylene-covered nitinol
stent graft. The Hemobahn device design characteristics, Food and Drug Administration phase I feasibility trial design
and results, phase II pivotal trial design, and single-site phase II trial results are reviewed. The long-term outcomes of
patients treated with angioplasty and Hemobahn stent grafting will determine the role of stent grafting in the manage-
ment of occlusive arterial lesions below the aortic bifurcation. (J Vasc Surg 2001;33:S124-8)
The growing acceptance of treating patients with
abdominal aortic aneurysms with endovascular techniques
is in the process of changing the landscape of vascular
surgery. Surgeons are trying to rapidly master and apply
catheter-based interventions. Concomitant with this revo-
lution in technical skills, vascular surgeons are “thinking
endovascular,” trying to identify appropriate targets out-
side of the abdominal aorta for endoluminal therapy.
Occlusive lesions of the iliac and femoral arteries represent
one commonly treated pathologic condition that might be
treated with a less invasive approach than standard open
surgical techniques.
Balloon angioplasty and stenting of iliac stenoses
are already part of the vascular surgeon’s armamentar-
ium. Although short stenoses of the common iliac
artery fare well with this approach, treating patients
with long-segment disease or complete occlusions,
lesions of the external iliac artery or femoral system,
smaller vessel diameters, critical limb ischemia, or poor
runoff results in markedly poorer outcomes.1-4 With the
use of Kaplan-Meier estimates after initially successful iliac
angioplasty and primary stenting (ie, initial failures elimi-
nated), Sullivan reported angiographic patencies in 101
arteries were 96%, 81%, and 73% at 6, 12, and 24 months,
respectively.5 Endovascular intervention for femoral dis-
ease has consistently been associated with poorer durabil-
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at the trailing end of the catheter (closest to the operator).
This knob pulls a single-fiber deployment line that releases
laced knots running along the length of the endoprosthe-
sis, allowing the nickel-titanium stent to expand (Fig 2).
Unlike most endoprostheses, the Hemobahn deploys
from hub to tip. The device is secured to the delivery
catheter in an essentially fully deployed configuration and
is then rolled or folded over itself onto the catheter. The
advantage of this design is that minimal device foreshort-
ening occurs during deployment, averaging 3 mm of
shortening in the 15-cm length Hemobahn endoprosthe-
sis. Radiopaque markers on the catheter further facilitate
placement under fluoroscopic guidance. The device is cur-
rently manufactured in 5-, 10-, and 15-cm lengths and in
diameters ranging from 6 to 13 mm.
CLINICAL TRIALS
The Hemobahn endoprosthesis is still considered an
investigational device in the United States but is in full
commercial use in many other countries worldwide.
Within the United States, the results of feasibility trials
from both the United States (phase I trial) and European
study sites have been reported to the Food and Drug
Administration, and a multicenter U.S.-based phase II
trial (Pivotal trial) is ongoing.
The phase I feasibility trial was conducted in three
U.S. centers as part of an international multicenter prod-
uct evaluation. This feasibility trial was part of a larger
international trial conducted with an identical protocol in
the three U.S. sites plus 14 European centers between
September 1996 and February 1998. One-year follow-up
data from both the U.S. and European centers were pre-
sented to the Food and Drug Administration in 1999. In
these trials the indications for intervention with the
Hemobahn endoprosthesis included atherosclerotic
lesions resulting in either chronic lifestyle-limiting claudi-
cation or critical limb ischemia. In this nonrandomized
multicenter trial, percutaneous access to the femoral artery
was obtained, and lesions in the iliac and femoral arteries
were treated by predilation with an angioplasty balloon.
Plaque debulking was not used in this trial. Antegrade
femoral access was used to treat lesions of the superficial
femoral artery. An 8F or 9F sheath was required to place
the Hemobahn endoprosthesis, depending on the diame-
ter of the device to be implanted. After angioplasty was
performed, a residual stenosis of <30% was required, as
was a minimal vessel diameter of 4.5 mm (Fig 3). Patients
with >30% stenosis after angioplasty were excluded from
enrollment in this trial. Patients had pretreatment ankle-
brachial indexes (ABI), color-flow duplex ultrasound
imaging (CFDU), and assignment to one of the categories
of chronic limb ischemia.7 At discharge after Hemobahn
placement, patients had the ABI and CFDU repeated and
then had follow-up evaluations at 1, 3, 6, and 12 months.
One hundred forty-one limbs were treated in 127 patients
with a total of 175 devices. Sixty-one limbs were treated
by 72 Hemobahn devices placed in the iliac arteries (32
common iliac, 29 external iliac), and 80 limbs were treated
Fig. 1 The prosthesis is composed of an ultra-thin (100-µm wall thickness, 30-µm internodal distance) expanded polytetraflouroethyl-
ene graft on the luminal surface attached to self-expanding nitinol (nickel-titanium) stent. The Hemobahn endoprosthesis deploys from
hub to tip in a proximal to distal direction. The device is secured to the delivery catheter in a fully deployed configuration, then folded
over itself onto the catheter. This design results in minimal device foreshortening during deployment.
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with 103 devices for femoral lesions. The mean iliac lesion
length was 6.9 cm, with a final post-treatment diameter of
7.2 mm. For femoral artery lesions, longer segments of
disease in smaller vessels resulted in a mean treatment
length of 13.1 cm with a diameter of 6.3 mm. Two major
(surgically repaired dissection, deep wound infection at
access site) and 22 minor complications (requiring mini-
mal or no treatment) were reported. Early (<30 days)
thrombosis occurred in four limbs (1 of 61 iliac arteries
[1.6%], 3 of 80 femoral arteries [3.8%]). Delayed resteno-
sis or reocclusion was recognized in an additional 4 (6.6%)
of 61 iliac arteries and 13 (16%) of 80 femoral arteries
after 1 year of follow-up. Primary and secondary patency
rates at 1 year based on CFDU imaging for iliac
Hemobahn devices were 91% and 95%, respectively. ABIs
rose from a preprocedure mean of 0.59 to 0.87 afterwards
and were maintained at the 0.85 level after 1 year. For the
femoral endoprostheses, 79% primary and 93% secondary
patency at 1 year was reported, with an increase from 0.60
to 0.94 at the immediate and 1-year intervals. The results
of this worldwide multicenter trial have been presented at
multiple symposia worldwide and have recently been pub-
lished.8-10
The U.S. Pivotal IDE clinical (phase II) trial is a ran-
domized multicenter trial involving 25 U.S. institutions.
Eligible patients are those with de novo or restenotic
occlusive superficial femoral artery lesions resulting in
lifestyle-limiting claudication or lower limb ischemia.
Patients with previous surgery or stenting at the treatment
site are excluded. The trial will evaluate 1-year primary
patency of lesions in the superficial femoral artery treated
with angioplasty alone versus angioplasty followed by
Hemobahn placement. Uncovered stent placement is not
part of this trial, because there are currently no stents with
Food and Drug Administration approval for use in the
femoral artery. The trial is recruiting patients for treatment
of stenoses or occlusions ≤13 cm long, with a superficial
femoral artery diameter of 4.8 to 13 mm. After initial
angioplasty, which can follow thrombolysis for occluded
segments, ≤50% residual stenosis is required. Patients with
>50% residual stenosis are excluded from participation in
this trial. After successful primary angioplasty defined by
the previously described criteria is achieved, patients are
randomized as to whether they will have a Hemobahn
endoprosthesis placed. The lesion treated cannot begin
within 0.5 cm of the profunda femoris artery and must
end 1 cm proximal to the knee joint. At least one-vessel
continuous run-off to the foot is required. All patients
receive periprocedural heparin and antiplatelet/aspirin
therapy. Trial enrollment began in June 1998 but was vol-
untarily postponed in December 1999 to allow the manu-
facturer to make minor changes to the delivery catheter.
These changes were designed to facilitate withdrawal of
the delivery catheter through the deployed endoprosthe-
sis. Patient enrollment is expected to resume in the fall of
2000 and be completed by April 2001. In the December
1999 to August 2000 enrollment hiatus, the manufactur-
ing site of the Hemobahn endoprosthesis is also being
transferred from California to the company’s primary
manufacturing division in Flagstaff, Arizona. One-year fol-
low-up and reporting of results is anticipated by the sum-
mer of 2002. To date, approximately 50% of targeted
patients have been enrolled and randomized. No pooled
data from multiple centers is available, but one center has
reported its preliminary results.11 Twenty-three patients
were randomized to percutaneous transluminal balloon
angioplasty (PTA) (11) or PTA plus Hemobahn place-
ment (12). Both groups reported an initial mean increase
in exercise ABIs, with an increase over pretreatment ABI
of 0.51 in patients treated with the Hemobahn endopros-
thesis and 0.42 in patients treated with PTA 1 month after
intervention. Of the 16 patients monitored for 6 months,
Fig. 2. Deployment occurs by pulling a deployment knob located at the proximal, or trailing, end of the catheter. This knob pulls a sin-
gle fiber deployment line that releases laced knots running along the length of the endoprosthesis, allowing the nitinol stent to expand.
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5 (71%) of the 7 patients treated by PTA alone have had
recurrent stenoses, whereas all 9 Hemobahn-treated arter-
ies remain primarily patent with normal waveforms and
CFDU imaging. Exercise ABIs at 6 months were increased
less than 0.15 versus pretreatment levels in five of six
patients treated with PTA, whereas nine patients treated
with Hemobahn had a mean 0.44 improvement in exer-
cise ABIs. Primary patency remained 100% in six patients
treated with Hemobahn monitored for 1 year.
Outside of these two manufacturer-sponsored trials,
anecdotal reports of Hemobahn endoprostheses
implanted for treatment of nonatherosclerotic lesions have
suggested potential application in managing femoral and
popliteal aneurysms, pseudoaneurysms, and entrapment
syndromes.12 A report by Burger et al13 includes images of
the Hemobahn endoprosthesis in proximity to the knee
joint with no angiographic narrowing despite full flexion
of the knee joint.
DISCUSSION
Occlusive lesions of the iliac and femoral arteries are
common clinical problems and have attracted the interest
of both physicians and manufacturers. Angioplasty of focal
iliac lesions with uncovered stent placement when appro-
priate has proven to be a durable, effective, and minimally
invasive therapy. As the lesions become longer, more com-
plex, or located below the inguinal ligament, patency with
these techniques decreases markedly. In smaller vessels
with bulky atheromatous disease or with extrinsic com-
pressive forces (as found at the adductor hiatus), mechan-
ical debulking with removal of plaque or chronic
thrombus may be required. Devices that facilitate remote
endarterectomy are being evaluated and may also poten-
tially improve outcomes of endoluminal stent grafting in
smaller diameter vessels. Open surgical bypass grafting
represents a more effective but more invasive treatment
option. The role of relining angioplastied arterial seg-
ments with a prosthetic graft may have merit, achieving
the advantages of an iliac or femoral bypass by a percuta-
neous approach or small groin incision.
Clinical trials of the Hemobahn endoprosthesis have
shown that if stenotic or occluded arteries can undergo
successful angioplasty to an adequate luminal caliber,
endoluminal stent grafting is possible. Whether endolumi-
nal stent grafting improves outcomes compared with
angioplasty alone or angioplasty plus uncovered stenting
remains unproven. However, results of the worldwide
multicenter trial data compared with historic control
data14,15 and preliminary phase II trial data suggest that
Hemobahn placement is at least as good as, if not superior
to, angioplasty with or without stenting. Long-term out-
comes of patients treated with the Hemobahn endopros-
thesis will reveal what role, if any, stent grafting will play
in the management of occlusive vascular lesions below the
aortic bifurcation.
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